Drugs.com - New Drug Approvals

FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to Xgeva

LAKE ZURICH, Ill., March 27, 2025 -- Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilar Bomyntra (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug...

Mar 29, 2025 - 07:23
 0
FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to Xgeva
LAKE ZURICH, Ill., March 27, 2025 -- Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilar Bomyntra (denosumab-bnht) of its operating company Fresenius Kabi has been approved by the U.S. Food and Drug...
Read More

Tags:

Previous Article

Not One, But Two, George W. Bush-Appointed Judges Grant Restraining Orders Again...

Next Article

Renewable Energy Provided More Than 50% Of UK Electricity In 2024

Related Posts

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to Prolia

FDA Approves Stoboclo (denosumab-bmwo), a Biosimilar to...

Mar 5, 2025  0

FDA Approves Romvimza (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor

FDA Approves Romvimza (vimseltinib) for the Treatment o...

Feb 17, 2025  0

FDA Approves Ensacove (ensartinib) for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FDA Approves Ensacove (ensartinib) for ALK-Positive Loc...

Feb 9, 2025  0